

Empax Centre provides structured psychedelic-assisted therapy programs for adults living with post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD), where these treatments are considered clinically appropriate.

This brochure is intended for people who have already expressed interest in, or inquired about, our programs. It offers general information only and is designed to support early, exploratory conversations. It does not replace individual medical advice or a formal consent process.

All treatment decisions at Empax Centre are made following a comprehensive assessment and discussion with your treating clinicians.

**WHAT IS PSYCHEDELIC-ASSISTED THERAPY?**

Psychedelic-assisted therapy refers to a clinically supervised treatment process that combines psychotherapy with the controlled use of certain psychedelic medicines. At Empax Centre, these medicines are administered within a broader therapeutic framework that includes:

- Careful medical and psychological screening
- Preparation therapy to support understanding, safety, and readiness
- One or more supervised dosing sessions in a clinical environment
- Integration therapy to support reflection and ongoing psychological care
- Participation is voluntary and based on informed consent. Not everyone who inquires will be eligible, and alternative options may be recommended.

**OUR PROGRAMS**

<p><i>MDMA-Assisted Therapy (MDMA-AT)</i></p> <p>For adults with Post-Traumatic Stress Disorder (PTSD)</p>	<p>MDMA-assisted therapy combines trauma-informed psychotherapy with MDMA, delivered in a carefully controlled clinical setting. During dosing sessions, MDMA may temporarily affect emotional processing, including fear responses and emotional openness. In some people, this may support engagement with therapeutic material that can otherwise feel difficult to approach. MDMA-AT is considered only after thorough assessment and is generally explored when established PTSD treatments have not provided sufficient benefit.</p>
<p><i>Psilocybin-Assisted Therapy (PSIL-AT)</i></p> <p>For adults with Treatment-Resistant Depression (TRD)</p>	<p>Psilocybin-assisted therapy combines psychotherapy with psilocybin, a naturally occurring psychedelic compound, within a structured clinical program. Psilocybin may temporarily alter perception, emotional awareness, and patterns of thinking, which for some people can support therapeutic exploration and insight when delivered with appropriate psychological support. PSIL-AT is generally considered for people whose depression has not responded adequately to standard treatments, following careful screening and discussion.</p>


MDMA and Psilocybin are unapproved medicines in Australia and are supplied at Empax Centre under the TGA Authorised Prescriber scheme, in accordance with relevant regulatory requirements.

**HOW THE TREATMENT PROCESS IS STRUCTURED**

While each program is tailored to the individual, most people who proceed move through the following stages:

<b>Screening and Assessment</b>	A comprehensive medical and psychological assessment is undertaken to determine whether the program is appropriate and safe. Please note that certain medications may need to be tapered; this will be discussed during screening. In some cases, alternative treatments or referrals may be recommended instead.
<b>Preparation Therapy</b>	If you proceed, you will work with a designated therapy team (two trained therapists). Preparation sessions focus on building therapeutic rapport, discussing expectations, and ensuring you feel informed about the process.
<b>Dosing Sessions</b>	Dosing sessions take place in a calm, private clinical environment. Your therapy team remains with you throughout the day, and an Authorised Prescriber psychiatrist oversees medical aspects of care. Sessions typically last most of the day, with time allocated for settling in, therapeutic support, and a supported close.
<b>Integration Therapy</b>	Integration sessions provide space to reflect on the experience and consider how it may relate to ongoing therapy and daily life. Integration is paced and supportive, with no expectation of specific outcomes.
<b>Follow-Up Support</b>	Once your treatment is complete, we will check in with you at designated intervals to monitor your progress and provide further support where appropriate.

A visual representation of our treatment program is provided below.



## SAFETY, OVERSIGHT, AND REGULATION

Safety and clinical governance are central to all Empax Centre programs. Measures include:

- **Thorough pre-treatment screening**
  - Continuous psychological and physical monitoring during dosing sessions
  - Clear post-session safety requirements, including overnight support arrangements
- **Ongoing access to medical and therapeutic review**
  - MDMA and psilocybin are not registered medicines in Australia. Their use involves uncertainties, and outcomes vary between individuals. Your care team will discuss potential risks, limitations of evidence, and alternative options in detail as part of the assessment and consent process.
- **A respectful, individualised approach**
  - People who inquire about these treatments often bring a mix of curiosity, caution, and uncertainty. At Empax Centre, questions and hesitations are welcomed. Our clinicians aim to provide clear information, professional care, and a respectful space to consider whether this approach is right for you.

There is no obligation to proceed at any stage.

## TREATMENT COST

Please note that MDMA and Psilocybin are not listed on the Pharmaceutical Benefits Scheme (PBS). The total cost of treatment typically ranges from \$12,000 to \$30,000, depending on your personalised treatment plan.

Current funding options include:

- **Medibank:** Medibank has partnered with Empax Centre and our hospital site partner, Perth Clinic to fund all costs associated with our TRD and PTSD program for eligible Medibank customers (existing and new). Before accessing Medibank funding support, all potential Empax clients must complete two out-of-pocket screening assessments totalling \$2,795.
- **Medicare:** A Medicare rebate is available for the Eligibility Review and Care Plan with a rebate ranging from \$255.90 to \$755.90. Our team can apply for this benefit on your behalf once we have been provided with a valid referral and details of your Medicare card.
- **DVA:** The Department of Veterans' Affairs (DVA) has announced funding coverage for eligible veterans, a significant step toward improving access for those with service-related trauma. Coverage has been confirmed for eligible Gold Card and White Card holders with an appropriate diagnosis (e.g., TRD).
- **WorkCover:** Case-by-case funding remains available for patients with treatment-resistant workplace trauma (PTSD/TRD), assessed on clinical need. This includes licensed private insurers (e.g., QBE, GIO) and government insurance schemes.
- **Mind Medicine Australia Patient Support Fund:** The Mind Medicine Australia Patient Support Fund is a charitable fund which subsidises treatment costs for Psychedelic-Assisted Therapy in Australia to support equitable access. The fund can provide up to 50% of treatment to a maximum of \$10,500 towards treatment and is available to those with limited assets and income.

If you would like to access additional funding options that are available to you, whether that be through your workers compensation insurer, accessing insurance through your superannuation fund or another option, the team at Empax Centre are happy to assist.

### **MAKING AN ENQUIRY**

If you would like to discuss whether psychedelic-assisted therapy may be appropriate for you, our team can provide further information about eligibility, assessment pathways, and practical considerations.

#### **Empax Centre**

**Phone:** 1300 539 006

**Email:** [clientcare@empaxcentre.com](mailto:clientcare@empaxcentre.com)

***Please note, Empax Centre is not a crisis service***

If you wish to proceed with the program, you will be asked to provide a referral from your GP or psychiatrist. In certain cases, supportive documents from other care providers may also be requested.

### **REGULATORY DISCLAIMER**

MDMA and Psilocybin are unapproved products and are only available through the TGA Authorised Prescriber scheme in approved clinical settings. Any prescribed medicine is for your use only. **MDMA and Psilocybin must not be shared, sold, or used outside the therapeutic setting.** Misuse or diversion is against the law and may result in serious consequences.

This information sheet does not replace medical advice; please consult your healthcare provider for personal guidance.